PRIME: 5 years experience

The European Medicines Agency's PRIority MEdicines (PRIME) scheme was set up in March 2016 to provide early and enhanced scientific and regulatory support to medicines that have the potential to significantly address patients' unmet medical needs.



How has PRIME helped patients benefit from new treatment options since its launch?



Supported the medicines evaluation process and reduced time to marketing authorisation.



Accelerated assessment confirmed at the time of marketing authorisation and increased chance to keep it until opinion.



Benefitted more complex medicines and/or applications with smaller datasets (advanced therapies, medicines for rare diseases).





Enhanced regulatory support and compliance with scientific advice led to higher success rate of marketing authorisation applications.



Broad range of unmet medical needs covered.


PRIME eligibility






Impact on marketing authorisation applications







CLICK HERE

For the five-year report on PRIME, visit the EMA website

The cut-off date for data collection is 30 June 2021.